Arrowhead Research announced this week that it has completed enrollment and dosing of the first cohort of patients in an ongoing Phase IIb trial of its hepatitis B drug ARC-520.
The open label, single ascending dose study is set to evaluate ARC-520 at doses of 1.0 mg/kg and 2.0 mg/kg. At each of the dose levels tested, 8 patients will be enrolled with 6 receiving ARC-520 and 2 receiving placebo.
The company reiterated its expectation that all patients will be dosed in the second quarter, with top-line results from the study available in the third quarter.